Who is sponsoring NCT05034133?

NCT05034133 is sponsored by Beijing Haidian Hospital.

What drugs are being tested in NCT05034133?

Interventions in NCT05034133: Durvalumab.

What condition does NCT05034133 study?

NCT05034133 studies Limited Stage Small Cell Lung Cancer.

Is NCT05034133 still recruiting?

NCT05034133 is currently status unknown. Last updated 5 September 2021.

Last reviewed 2021-09-05 · How we verify

NCT05034133

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer

Status unknown Phase 2 Last updated 5 September 2021

What this trial tests

Phase 2 trial testing Durvalumab in Limited Stage Small Cell Lung Cancer in 20 participants. Status unknown.

Timeline

1 September 2021

Primary endpoint
31 August 2023

31 August 2024

Quick facts

Lead sponsor	Beijing Haidian Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 September 2021
Primary completion	31 August 2023
Estimated completion	31 August 2024
Sites	1 location across China

Drugs / interventions tested

Durvalumab — full drug profile →

Conditions studied

Limited Stage Small Cell Lung Cancer — all drugs for Limited Stage Small Cell Lung Cancer →

Sponsor

Beijing Haidian Hospital

Who can join

18 and older, any sex, with Limited Stage Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single arm Phase II study, in which 6 cycles of durvalumab with chemotherapy (Etoposide and Cisplatin) and durvalumab followed by Sequential radiotherapy for limited stage small cell lung cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer.
Schlick B, Shields MD, Marin-Acevedo JA, Patel I, et al · · 2022 · cited 12× · PMID 35716328 · DOI 10.1007/s11864-022-00989-7
State of the art in treatment of small cell lung cancer.
Behrouzi R, Blackhall F. · · 2025 · cited 1× · PMID 40964483 · DOI 10.1177/17588359251363518

Verify or expand the search:

Other trials of Durvalumab

Trials testing the same drug.

NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting

Other recruiting trials for Limited Stage Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06943235 — Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in th · Phase 2 · recruiting
NCT06256237 — Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small · Phase 2 · recruiting
NCT06117774 — Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) · Phase 3 · recruiting
NCT05623267 — Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT · Phase 2, PHASE3 · recruiting
NCT05443646 — Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients · Phase 2 · recruiting

Other Beijing Haidian Hospital trials

Trials by the same sponsor.

NCT07257471 — Application Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy · recruiting
NCT07257458 — Application of Methylation Markers in Early Detection and MRD Monitoring of Lung Cancer · recruiting
NCT06973499 — Exploratory Study of the Microbiome of Upper Gastrointestinal in the Pathogenesis of Multiple Primary Lung Cancer · completed
NCT03098914 — Clinical Characteristics and Microbiology of Community-Acquired Pneumonia · unknown
NCT03170830 — Diagnostic Value of CircRNA-Uck2 for Acute Myocardial Infarction · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05034133 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Haidian Hospital
Last refreshed: 5 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05034133.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing